Brom-ergocryptine in the treatment of phenothiazine-induced galactorrhoea.
D000328:Adult; D000568:Amenorrhea / Q000188:drug therapy; D000639:Amitriptyline / Q000009:adverse effects; D014150:Antipsychotic Agents / Q000009:adverse effects*; D004876:Ergot Alkaloids / Q000627:therapeutic use*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D005687:Galactorrhea / Q000139:chemically induced / Q000188:drug therapy*; D006801:Humans; D007775:Lactation Disorders / Q000188:drug therapy*; D007986:Luteinizing Hormone / Q000097:blood; D008875:Middle Aged; D010546:Perphenazine / Q000009:adverse effects; D011247:Pregnancy; D011352:Procyclidine / Q000009:adverse effects; D011388:Prolactin / Q000097:blood; D013881:Thioridazine / Q000009:adverse effects; D014268:Trifluoperazine / Q000009:adverse effects
D014150:Antipsychotic Agents; D004876:Ergot Alkaloids; D000639:Amitriptyline; D014268:Trifluoperazine; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D011352:Procyclidine; D010546:Perphenazine; D013881:Thioridazine